Home >ビル・アンドリュース博士について

ビル・アンドリュース博士について【 Bill Andrews, Ph.D. 】

老化による疾病・治療の先駆者 "ビル・アンドリュース博士"

ビル・アンドリュース博士は、バイオテクノロジー産業の分野に30年もの間、身を置き、特にここ18年ほどは"ヒト細胞におけるテロメア短縮"へ介入することにより人間の寿命を延長する方法を探索することに焦点を当てています。
博士は、1981年にジョージア大学にて分子および集団遺伝学の分野で博士号を取得し、その後はArmos社およびCodon社にて上級研究員、Codon社およびジェロン（Geron）社にて分子生物学部門ディレクター、そしてEOS Biosciencesでは、技術開発部門のディレクターを歴任。
ネバダ州リノ市のバイオテクノロジー企業「Sierra Sciences, LLC」の創設者であり、現在、その社長および最高経営責任者を併任しています。
Sierra Sciences社では、ヒト細胞の内因性テロメラーゼの発現を一過性に誘導する薬物の発見に専ら取り組んでおり、既にそのような薬物を30種以上同定し、現在は、それらの作用機序の解明にも取り組んでいます。
ジェロン社での分子生物学部門ディレクター在任時に博士は、他の共同研究者らと共に"ヒトテロメラーゼ"のRNAおよびタンパク質両方の構成成分の発見に重要な貢献をし、1997年には本研究に対して米国の「その年の著名な国内発明家・発案者（National Inventor of the Year）」として第2位を受賞しました。
現在では、TAM-818などテロメラーゼに関する【43】もの米国発行の特許に発案者として、その名前を連ねています。


※ビル・アンドリュース博士のプレゼンテーション動画一覧
SierraSciences YouTubeチャンネル

U.S.-Issued Patents

  • DNA encoding an antigenic protein derived from Eimeriatenellaand vaccines for prevention of coccidiosis caused by Eimeriatenella
      Patent Number: US4874705, Issued 1989-10-17
  • DNA encoding an antigenic protein derived from Eimeriatenellaand vaccines for prevention of coccidiosis caused by Eimeriatenella
      Patent Number: US5187080, Issued 1993-02-16
  • Mammalian telomerase
      Patent Number: US5583016, Issued 1996-12-10
  • Mutagenesis methods and compositions
      Patent Number: US5702931, Issued 1997-12-30
  • Assays for the DNA component of human telomerase
      Patent Number: US5776679, Issued 1998-07-07
  • Protease-resistant thrombomodulinanalogs
      Patent Number: US5827824, Issued 1998-10-27
  • Mammalian telomerase
      Patent Number: US5837857, Issued 1998-11-17
  • Methods and reagents for regulating telomere length and telomerase activity
      Patent Number: US5858777, Issued 1999-01-12
  • Protease-resistant thrombomodulinanalogs
      Patent Number: US5863760, Issued 1999-01-26
  • RNA component of mouse, rat, Chinese hamster and bovine telomerase
      Patent Number: US5876979, Issued 1999-03-02
  • Mammalian telomerase
      Patent Number: US5958680, Issued 1999-09-28
  • RNA component of telomerase
      Patent Number: US6013468, Issued 2000-01-11
  • Mammalian telomerase RNA gene promoter
      Patent Number: US6054575, Issued 2000-04-25
  • Protease-resistant thrombomodulinanalogs
      Patent Number: US6063763, Issued 2000-05-16
  • Mammalian telomerase
      Patent Number: US6258535, Issued 2001-07-10
  • Telomerase
      Patent Number: US6261836, Issued 2001-07-17
  • Peptides related to TPC2 and TPC3, two proteins that are coexpressedwith telomerase activity
      Patent Number: US6300110, Issued 2001-10-09
  • Mammalian telomerase
      Patent Number: US6320039, Issued 2001-11-20
  • Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
      Patent Number: US6444650, Issued 2002-09-03
  • Human telomerase catalytic subunit: diagnostic and therapeutic methods
      Patent Number: US6475789, Issued 2002-11-05
  • Mammalian telomerase
      Patent Number: US6548298, Issued 2003-04-15
  • Promoter for telomerase reverse transcriptase
      Patent Number: US6610839, Issued 2003-08-26
  • Cells immortalized with telomerase reverse transcriptase for use in drug screening
      Patent Number: US6617110, Issued 2003-09-09
  • Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
      Patent Number: US6627619, Issued 2003-09-30
  • Methods and compositions for modulating telomerase reverse transcriptase (TERT) expression
      Patent Number: US6686159, Issued 2004-02-03
  • Telomerase promoter driving expression of therapeutic gene sequences
      Patent Number: US6777203, Issued 2004-08-17
  • Method for detecting polynucleotides encoding telomerase
      Patent Number: US6808880, Issued 2004-10-26
  • Telomerase
      Patent Number: US6921664, Issued 2005-07-26
  • Genes for human telomerase reverse transcriptase and telomerase variants
      Patent Number: US6927285, Issued 2005-08-09
  • Methods for detecting nucleic acids encoding human telomerase reverse transcriptase
      Patent Number: US7005262, Issued 2006-02-28
  • Telomerase
      Patent Number: US7056513, Issued 2006-06-06
  • Mammalian cells that have increased proliferative capacity
      Patent Number: US7195911, Issued 2007-03-27
  • Regulatory segments of the human gene for telomerase reverse transcriptase
      Patent Number: US7199234, Issued 2007-04-03
  • Telomerase expression repressor proteins and methods of using the same
      Patent Number: US7211435, Issued 2007-05-01
  • Assays for TERT promoter modulatory agents using a telomerase structural RNA component
      Patent Number: US7226744, Issued 2007-06-05
  • Nucleic acids encoding human telomerase reverse transcriptase and related homologs
      Patent Number: US7262288, Issued 2007-08-28
  • Methods and compositions for modulating telomerase reverse transcriptase (TERT) expression
      Patent Number: US7279328, Issued 2007-10-09
  • Antibody to telomerase reverse transcriptase
      Patent Number: US7285639, Issued 2007-10-23
  • Identifying and testing antisense oligonucleotides that inhibit telomerase reverse transcriptase
      Patent Number: US7297488, Issued 2007-11-20
  • Telomerase promoters sequences for screening telomerase modulators
      Patent Number: US7378244, Issued 2008-05-27
  • Treating cancer using a telomerase vaccine
      Patent Number: US7413864, Issued 2008-08-19
  • Muteinsof human telomerase reverse transcriptase lacking telomerase catalytic activity
      Patent Number: US7517971, Issued 2009-04-14
  • Nucleic acid compositions for eliciting an immune response against telomerase reverse transcriptase
      Patent Number: US7560437, Issued 2009-07-14
  • Increasing the proliferative capacity of cells using telomerase reverse transcriptase
      Patent Number: US7585622, Issued 2009-09-08
  • Human telomerase reverse transcriptase polypeptides
      Patent Number: US7622549, Issued 2009-11-24
  • Antibody to telomerase reverse transcriptive
      Patent Number: US7750121, Issued 2010-07-06
  • Telomerase expression repressor proteins and methods of using the same
      Patent Number: US7795416, Issued 2010-09-14
  • Regulatory segments of the human gene for telomerase reverse transcriptase
      Patent Number: US7879609, Issued 2011-02-01
  • Kit for detection of telomerase reverse transcriptase nucleic acids
      Patent Number: US8222392, Issued 2012-07-17
  • Human telomerase catalytic subunit
      Patent Number: US8236774, Issued 2012-08-07

Page top

研究チームスタッフ   〈 Sierra Sciences,LLC 〉

【 Scientific Staff 】

Laura A. Briggs, Ph.D.  (Vice President of Research and Discovery）

Laura Briggs received her B.S. degree in Nutrition in 1993 and her Ph.D. in Environmental Science and Health in 2000 from the University of Nevada, Reno. After a one-year post-doctoral position at UNR she joined Sierra Sciences in 2001. In addition to coordinating research and development at Sierra Sciences, Dr. Briggs is also currently serving as the biology Lab Coordinator for Truckee Meadows Community College (TMCC) and has collaborated on research projects at the V.A. Medical Center in Reno, Nevada.



Lancer Brown, M.S.  (Program Director of Screening）

Lancer Brown received his B.S. and M.S. degrees in Biotechnology in 2003 from the University of Nevada, Reno and was one of three students in the inaugural advanced BS/MS Biotechnology Program. He distinguished himself by being the first student to complete the program. Lancer came to Sierra Sciences as an intern while completing his degree. Following graduation, he joined Sierra Sciences full-time where he has proven to have remarkable ability to engineer genes and DNA. He has recently been promoted to program director of screening.



Hamid Mohammadpour, Ph.D.

Dr. Mohammadpour has been a senior scientist at Sierra Sciences for over a decade, and currently heads the Cell Biology department, where he oversees the cell culture fundamental to the company's screening efforts. In addition to tissue and cell culture, he also specializes in protein chemistry and molecular biology. For over twenty years, Dr. Mohammadpour has been a researcher at several Universities and biotech companies. He has a B.S. in chemistry from the University of Nebraska, Lincoln and worked for the University of Nebraska Medical center. Prior to completing his Ph.D. in cell and molecular biology, he was a researcher at the University of Nevada School of Medicine.



【 Business Staff 】

Lonnie Klaich  (Vice President of Finance & Administration）

Lonnie Klaich leads the finance and administrative functions of Sierra Sciences. He is responsible for financial and government reporting, financial planning, budgeting, and human resources. Mr. Klaich is a financial and business planning professional who has held financial leadership roles in the health care industry for twenty-five years. These have ranged from Insurance company, to Hospital, to the largest Neurosurgery Group in Northern Nevada. He has also served time with the gaming industry and freight & logistics industry. Lonnie is graduate of the University of Nevada, Reno with Bachelors of Science degree focusing on Accounting & Finance.



【 Scientific Advisory Board 】

Bryant Villeponteau, Ph.D.

While working with Dr. Andrews at Geron, Dr. Villeponteau shared the 1997 2nd place Inventor of the Year Award. Dr. Villeponteau is also an internationally recognized expert in the aging process caused by oxidative stress. Dr. Villeponteau served as President of Healthspan Sciences.






Federico Gaeta, Ph.D.

Dr. Gaeta identified the first potent, small molecule, inhibitors of human telomerase. He is the sole inventor of universal therapeutic cancer vaccine technologies based on telomerase, currently being evaluated in human clinical trials. Dr. Gaeta is an experienced executive with major pharmaceutical and biotechnology companies in the area of new drug discovery and development.





Judith Campisi, Ph.D.

Dr. Campisi is a leading authority on telomerase, cellular senescence and the cell cycle.








Joel Hedgpeth, Ph.D.

Joel Hedgpeth founded Codon Corporation, a biotechnology company that was acquired by Schering, AG in 1990. He served as Vice President of Basic Research at Berlex Biosciences (a US subsidiary of Schering, AG) until 1993. Dr. Hedgpeth was acting Chief Scientific Officer of Epoch Biosciences (NASDQ; EBIO) until 2002. Dr. Hedgpeth received his degree with Herbert W. Boyer (founder of Genentech) at the University of California, San Francisco and after postdoctoral work at the University of Geneva, was a visiting professor at the Pasteur Institute (Paris) and a Research Fellow at the Howard Hughes Institute, UCSF.



Judith Campisi, Ph.D.

Jerry W. Shay, Ph.D., Professor and Vice Chairman
  Department of Cell Biology
  Associate Director Simmons Comprehensive Cancer Center
  UT Southwestern, Dallas, Texas.

Woodring 'Woody' Wright, Ph.D., Professor of Cell Biology UT Southwestern, Dallas, Texas.
http://www.swmed.edu/home_pages/cellbio/shay-wright/

Page top